title: Fulminant hepatitis C virus infection.
authors.forename: M
authors.initials: M
authors.lastname: Schirmer
authors.forename: W
authors.initials: W
authors.lastname: Vogel
authors.forename: J
authors.initials: J
authors.lastname: Thaler
authors.forename: K
authors.initials: K
authors.lastname: Grünewald
authors.forename: F
authors.initials: F
authors.lastname: Umlauft
authors.forename: F
authors.initials: F
authors.lastname: Geisen
authors.forename: U
authors.initials: U
authors.lastname: Zilian
authors.forename: G
authors.initials: G
authors.lastname: Konwalinka
mesh_terms: D015762:2-Chloroadenosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000410:Alanine Transaminase / Q000097:blood; D004796:Clinical Enzyme Tests; D003839:Deoxyadenosines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006526:Hepatitis C / Q000175:diagnosis / Q000635:transmission*; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy; D008875:Middle Aged; D065227:Transfusion Reaction
chemical_list: D003839:Deoxyadenosines; D015762:2-Chloroadenosine; C036854:2'-chloro-2'-deoxyadenosine; D000410:Alanine Transaminase